Skip to main content
Home
  • About Us
    • Our Credo
    • Board of Directors
      • Committees of the Board
    • Management Council
    • Sustainability
    • Manufacturing
    • Quality
    • Code of Conduct
    • Our History
    • Milestones and Awards
  • Our Presence
    • Australia
    • Europe
    • Kenya
    • Malaysia
    • Morocco
    • Nepal
    • South Africa
    • Sri Lanka
    • Uganda
    • United Kingdom
    • USA
  • Our Offerings
    • Our Therapies
      • Respiratory
        • Asthma
        • Paediatric Asthma
        • COPD
        • Nebulization
      • HIV/AIDS
      • Oncology
      • Other Therapies
    • Cipla Generics
    • OTC – Cipla Health
    • Cipla Diagnostics
    • API
  • Covid Care
  • Investors
    • Financials & Filings
      • Quarterly Results
      • Investor Presentation
      • Annual Reports
      • Scheme of Arrangement
    • Corporate Governance
    • Cipla at a Glance
      • Board Of Directors
      • Committees of the Board
    • Investor Resources
    • Shareholding Pattern
    • Intimation to Stock Exchange
    • Unclaimed Data
    • Investor Contact
    • Disclaimer
  • Careers
    • Culture and Values
    • Life at Cipla
    • Job Search
  • Media Centre
    • Media Releases
    • In The News 
    • Leaders Speak
  • Corporate Social Responsibility
    • Cipla Foundation
      • Annual Report
        • 2020-21
        • 2019-20
      • Focus Areas
      • Cipla Palliative Care & Training Centre
    • CSR Policy
    • CSR Committee
    • Approved CSR Projects
      • 2022-23
      • 2021-22
  • Contact Us
  • Global
    • Kenya
    • South Africa
    • Sri Lanka
    • Uganda
    • United Kingdom
    • U.S.A

Breadcrumb

  • Home
  • Media centre
  • News

In the news

Quick Explore

  • Media Releases

Featured News

30 Apr 2021

Making India breathe free beyond Covid-19

Read more
24 Apr 2021

Keeping purpose alive, amidst the new reality

Read more
19 Apr 2021

Need To Create Right Ecosystem And Mentorship For Women To Excel, Says Samina Hamied

Read more
29 Jan 2021

Cipla’s Yusuf K Hamied is India’s medicine man

Read more
News 2022
11 Jan 2022 Addressing the silent killer: Chronic Obstructive Pulmonary Disease
03 Jan 2022 Indian pharma industry hopes to maintain growth trajectory in the new year

Corporate Information

  • About Us
  • Board of Directors
  • Code of Conduct
  • Committees of the Board
  • Management Council
  • Sustainability
  • Manufacturing
  • Milestones and Awards
  • Our Credo
  • Our History
  • Quality

Our Presence

  • Our Presence
  • Australia
  • Europe
  • Kenya
  • Malaysia
  • Morocco
  • Nepal
  • South Africa
  • Sri Lanka
  • Uganda
  • United Kingdom
  • USA

Our Offerings

  • Our Therapies
  • Respiratory
  • Asthma
  • Paediatric Asthma
  • COPD
  • Nebulization
  • HIV/AIDS
  • Oncology
  • Cipla Generics
  • Our Offerings
  • OTC – Cipla Health
  • Cipla Diagnostics
  • API

Media

  • Media Center
  • Media Releases
  • In the News

Investor Information

  • Investors
  • Quarterly Results
  • Investor Presentation
  • Annual Reports
  • Corporate Governance
  • At a Glance
  • Board Of Directors
  • Committees of the Board
  • Investor Resources
  • Shareholding Pattern
  • Intimation to stock Exchanges
  • Unclaimed Data
  • Investor Contact
  • Disclaimer

Cipla Foundation

  • Corporate Social Responsibility
  • CSR Policy
  • CSR Committee
  • Cipla Foundation
  • Annual Report 2019-20
  • Covid Response
  • Cipla Palliative Care & Training Centre

Career Sitemap

  • Careers
  • Culture and Values
  • Life at Cipla

Quick Links - Footer

  • Privacy Policy
  • Disclaimer
  • Contact Us
  • Sitemap
  • Caution Notice - Recruitment Fraud
  • Drug Safety Reporting

Related Links

  • breathefree.com
  • ciplamed.com
  • ciplapalliativecare.org
  • Remdesivir Supply Details - Maharashtra

© Copyright 2019 Cipla Inc. All rights reserved

  •  
  •  
  •  
  •  
  •  

Subscribe to Cipla Newsletter

  •  
  •  
  •  
  •  

Mobile Footer Menu

  • Remdesivir Supply Details - Maharashtra
  • Caution Notice - "Recruitment Fraud"
  • Contact Us
  • Disclaimer
  • Privacy Policy

© Copyright 2019 Cipla Inc. All rights reserved

×